Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results

NEXT STORY
New Lactation Rooms Added to the ABOG Educational Foundation Test Center
PREV STORY
Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke

AST-OPC1 has Demonstrated Positive Safety Profile and Promising Signs of Efficacy in a Phase ...

author_avatar
NASDAQ Market News

Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 – a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics

ALG.APV-527 Engineered to Engage the Immune System for the Potential Treatment of Multiple Solid ...

author_avatar
NASDAQ Market News

Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage

author_avatar
NASDAQ Market News